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Sirs:
Classic Timothy syndrome (TS) is a rare congenital
arrhythmia disorder with dysfunction in multiple organ
systems, clinically characterized by long QT syndrome and
syndactyly. These unique features may be accompanied by
congenital cardiac defects, immune deﬁciency and autism
[12]. The ﬁrst cases of TS were described in 1992 and 1995
as sporadic cases of long QT syndrome, congenital heart
disease and syndactyly [4–6]. To date, only 25 cases of
classic TS have been reported in the literature [11]. Classic
TS is caused by a single missense mutation G406R of exon
8A of the Cav1.2 L-type calcium channel gene (CAC-
NA1C) and is inherited in an autosomal dominant fashion,
although it usually is the result of a de novo mutation [11,
12]. This gain-of-function mutation results in an impaired
open-state voltage-dependent inactivation of the L-type
calcium channel, ultimately leading to a markedly pro-
longed myocardial action potential [12, 13]. A rare variant
of TS with only two reported cases in the literature so far is
caused by two different point mutations of exon 8 of the
CACNA1C gene (G406R or G402S) and is clinically
characterized by long QT syndrome in the absence of
syndactyly [10]. As a result of prolonged QT-interval,
patients with TS are prone to life-threatening ventricular
arrhythmias [10–12]. Besides cardiac arrhythmias, mani-
festations of TS include congenital heart defects like
ventricular septal defects, patent ductus arteriosus, hyper-
trophic cardiomyopathy and Tetralogy of Fallot [11]. Since
the Cav1.2 L-type calcium channel is widely expressed in
multiple adult and fetal tissues including gastrointestinal
system, brain, lungs, immune system and testis, extracar-
diac manifestations like facial dysmorphy, myopia,
immune deﬁciency with recurrent infections, intermittent
hypoglycemia, and hypothermia are common in patients
with TS [11]. Many children with TS present with devel-
opmental delay, including language, motor, and general-
ized cognitive impairment [12].
We report on a now two years old female child with TS.
The patient had already prenatally been diagnosed with
intermittent 2:1 atrioventricular block and fetal bradycardia.
On fetal echocardiography, a small muscular ventricular
septal defect without other structural abnormalities was
present. After 34 weeks of gestation the child was delivered
by caesarean section because of premature rupture of
membranes and pathological cardiotocography. Postnatal
adaptation was normal with an APGAR score of 8/9 and 10.
Umbilical artery pH was 7.35. Physical examination
revealed syndactyly of ﬁngers 3–5 of both hands and syn-
dactyly of toes 1–3 of both feet. In addition the patient
presented with lower set ears and bald head (Fig. 1). Initial
ECG exhibited a prolonged QT-interval (QTc 600 ms), 2:1
atrioventricular block and a heart rate of 60/min (Fig. 2).
Echocardiography demonstrated hypertrophic cardiomy-
opathy, a small muscular ventricular septal defect and a
patent ductus arteriosus. Diagnosis of TS was established
based on the ECG ﬁndings and the typical clinical features
and was conﬁrmed by molecular genetic analysis, which
showed the typical G406R mutation of the CACNA1C
gene. Because of the markedly prolonged QT-interval and
the reported malignant course of TS, anti-arrhythmic treat-
ment with mexiletine (10 mg/kg/d, administered 3 times
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DOI 10.1007/s00392-011-0358-4daily, every 8 h) was started on the ﬁrst day of life. Within
the ﬁrst 4 days of life the patient developed progressive
heart failure because of persistent 2:1 atrioventricular block
and a hemodynamically signiﬁcant patent ductus arteriosus.
Therefore, the ductus arteriosus was surgically ligated and
an epicardial VVI-pacemaker (100/min) was implanted on
day 4 of life. Soon after closure of the ductus arteriosus and
after spontaneous restoration of normal atrioventricular
conduction due to a now comparatively shorter QT-interval
(QTc 560 ms) after starting the patient on mexiletine,
Fig. 1 Characteristic
phenotypic features of Timothy
syndrome: bald head and lower–
set ears, webbing of ﬁngers and
toes
Fig. 2 ECG after birth showed a prolonged QT interval (QTc 600 ms), 2:1 atrioventricular block and signiﬁcant bradycardia (ventricular rate
60/min)
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123cardiac function recovered. QT-interval was shortened
to 560 ms on continued anti-arrhythmic treatment with
mexiletine, the patient was in stable sinus rhythm and no
ventricular arrhythmias occurred. An extracardiac internal
cardioverter deﬁbrillator (ICD) system (Medtronic Secura

VR) was implanted at the age of ﬁve months and a body
weight of 4.5 kg (Fig. 3). The extracardiac ICD-system
consists of an epicardial bipolar pace-/sense electrode
(Medtronic CapSure
 Epi), sutured to the epicardium of the
left ventricle and a subpleural deﬁbrillation lead (Medtronic
Transvene
), placed in the 3rd or 4th intercostal space. The
ICD-device was placed infradiaphragmatically (Fig. 3).
Intraoperative testing revealed a deﬁbrillation threshold
below 5 J and did not change in subsequent testings
(3 months, 1 and 2 years after implantation). By the time of
ICD-implantation, the VVI-pacemaker was removed. Sur-
gery and postoperative course were uneventful and the
patient was discharged home two weeks later. The patient
was seen on a regular basis in our outpatient clinic with an
uneventful course. At the age of 21 months, the patient
developed an episode of fast polymorphic ventricular
tachycardia (Fig. 4), after she had refused her medication
due to upper respiratory tract infection. Ventricular tachy-
cardia was successfully terminated by the internal cardio-
verter deﬁbrillator (Fig. 4). In order to prevent future
tachycardia and deﬁbrillator discharges, propranolol (2 mg/
kg/d, administered 3 times daily, every 8 h) was added.
Since then, the patient did not present with ventricular
tachycardia again. No adverse side effects of either mexil-
etine treatment or propranolol treatment became evident to
date. She shows some developmental delay regarding motor
and speech development but is otherwise in good clinical
condition.
The presence of long QT syndrome and the risk for life-
threatening ventricular tachyarrhythmias is the limiting
factor of TS. Since ventricular tachyarrhythmia is the
leading cause of death in patients with TS, effective anti-
arrhythmic medication and an implantable cardioverter
deﬁbrillator are the mainstay of therapy. Due to the small
number of patients, no validated drug-therapy has been
established so far. As in other forms of long QT syndrome
anti-adrenergic b-blockers are reported to be a treatment
option. Additionally calcium channel blockers and ranol-
azine, a novel multichannel inhibitor have been used to
prevent ventricular tachyarrhythmia [1, 2, 7, 9, 11]. Except
of one reported case, where an adult patient suffering from
a rare variant of TS (TS2) was treated with a combination
of verapamil and ranolazine [7], none of these drugs was
proven to reliably prevent life-threatening ventricular
tachycardia in patients with classic TS over a longer period
of time. In our patient, we successfully used mexiletine, a
class IB anti-arrhythmic drug known to shorten QT-Inter-
val and effectively suppress the development of ventricular
tachycardia in patients with long QT syndrome type 3 [8].
No ventricular tachyarrhythmias were observed until the
age of 21 months, when the patient developed torsades de
pointes tachycardia after having refused to take her medi-
cation. This emphasizes the highly malignant course and
imperative need for a regular intake of the anti-arrhythmic
medication in patients with TS. Despite an uneventful
course until then, b-blocker medication was added to
provide a maximum of patient safety. Since it is not
uncommon in children to refuse part of their medication, a
second agent with a different way of action could improve
the patient0s safety regarding the prevention of ventricular
tachycardia. In order to control heart rate in the presence of
2:1 atrioventricular block, cardiac pacemakers are usually
placed within the ﬁrst days of life or early in infancy [5,
11]. Due to the malignant course of TS with a reported
average age at death of 2.5 years, implantable cardioverter
deﬁbrillators are most important in preventing sudden
cardiac death in individuals with TS and should be con-
sidered in every patient with conﬁrmed diagnosis as soon
as body weight allows the procedure for primary prophy-
laxis of sudden cardiac death even in patients without
documented ventricular tachycardia [11]. In our patient an
extracardiac ICD-system with a subpleural shock electrode
(modiﬁed according to [3]) was placed at a body weight of
4.5 kg (Fig. 3).
In conclusion, patients with TS are at high risk for
sudden cardiac death due to life-threatening ventricular
tachyarrhythmias. Drug therapy to prevent ventricular
tachyarrhythmia has not been validated due to the small
Fig. 3 Chest X-ray after implantation of an extracardiac cardioverter
deﬁbrillator system at the age of ﬁve months
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123number of patients but medication with mexiletine seems
to be effective in patients with classic TS and should be
combined with a b-blocking agent to counteract sympa-
thetic activity. In spite of antiarrhythmic medication
implantation of an internal cardioverter deﬁbrillator is
mandatory already in infancy.
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Fig. 4 At the age of 21 months, patient developed Torsade de pointes ventricular tachycardia which was successfully terminated by ICD
discharge (15 J)
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